Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.49 |
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601600 | 1.00 | HSD17B10 (0.53) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL7081683 | 0.87 | ACACB (0.49) | PKMNNMTACACBKDM4EKLKB1 | |
| SCHEMBL3604889 | 0.87 | ACACB (0.49) | PKMNNMTACACBKDM4EKLKB1 | |
| SCHEMBL25178744 | 0.85 | ACACB (0.46) | PKMNNMTACACBKDM4EKLKB1 | |
| SCHEMBL22444690 | 0.85 | ACACB (0.46) | PKMNNMTACACBKDM4EKLKB1 | |
| SCHEMBL30510332 | 0.85 | ACACB (0.46) | PKMNNMTACACBKDM4EKLKB1 | |
| SCHEMBL7945973 | 0.84 | ACACB (0.44) | PKMNNMTACACBKDM4ETPH1 | |
| SCHEMBL3861143 | 0.84 | ACACB (0.44) | PKMNNMTACACBKDM4ETPH1 | |
| SCHEMBL31370293 | 0.84 | HSD17B10 (0.51) | HSD17B10SLC7A5PTGS1PKMALPI | |
| SCHEMBL25356889 | 0.82 | ITGB3 (0.53) | HSD17B10SLC7A5PTGS1PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| CN-118201966-A | Human transferrin receptor binding antibody-peptide conjugates | 肽梦想株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| EP-1909814-B1 | Peptides for induction and enhancement of apoptosis in tumor cells | GEORG AUGUST UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS OHNE BEREICH HUMANMEDIZIN (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-8334258-B2 | Administering gonadotropin-hormone-releasing hormone (GnRH) antagonist peptide for inducing/enhancing apoptosis of breast cancer or malignant melanoma or gynaecological cancer | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS (UNIVERSITÄTSMEDIZIN) (DE) | 2012-12-18 | — | — | US | disclosed |
| US-20080167250-A1 | Method For Induction and Enhancement of Apoptosis In Tumor Cells | GEORG-AUGUST-UNIVERSITAET GOETTINGEN, STIFTUNG OEFFENTLECHEN RECHTS, BEREICH HUMANMEDIZIN (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1909814-A1 | METHOD FOR INDUCTION AND ENHANCEMENT OF APOPTOSIS IN TUMOR CELLS | Georg-August-Universität Göttingen Stiftung des Öffentlichen Rechts (Bereich Humanmedizin) (DE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012430-A1 | METHOD FOR INDUCTION AND ENHANCEMENT OF APOPTOSIS IN TUMOR CELLS | GEORG-AUGUST-UNIVERSITÄT-GÖTTINGEN (DE) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | HSD17B10 4549/4885SLC7A5 308/4885PTGS1 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.